 |
 |
 |
||||||||||||||
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
||||
| < 2006 News Listings | ||||||||||||||||
|
Commission For Increlex For Primary IGFD Treatment - Quick Facts 
RTTNews May 31, 2006 Tercica Inc. announced that it received orphan medicinal product status from European Commission for its Increlex for the treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects. Tercica noted that this orphan medicinal product status grants the company the market exclusivity in the European Union for 10 years after marketing approval. The company said it targets to launch Increlex for the EU in 2007. Tercica said Increlex was approved for severe Primary IGFD by FDA on August 30, 2005 and received orphan drug exclusivity in US for this indication. Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved. |
|
|
Copyright ©2007 Rho Capital Partners, Inc.